IDEAS home Printed from https://ideas.repec.org/a/taf/quantf/v2y2002i3p224-227.html
   My bibliography  Save this article

Economies of scale in innovations with block-busters

Author

Listed:
  • D. Sornette

Abstract

Are large-scale research programmes that include many projects more productive than smaller ones with fewer projects? This problem of economies of scale is relevant for understanding recent mergers, in particular in the pharmaceutical industry. We present a quantitative theory based on the characterization of distributions of discounted sales S resulting from new innovations. Assuming that these complementary cumulative distributions have fat tails with approximate power law structure S-α, we demonstrate that economies of scales are realized if and only if α<1. 'Economies of scale' is here understood according to the criterion that the probability to earn more than any fixed factor proportional to its size N is larger for the merged company C=A+B of size NA+NB than for any of the two component companies A and B with size NA and NB. In essence, the mechanism underlying the 'economies of scale' is that a very large payoff from a successful project can pay for all of the losing projects. Some empirical evidence suggests that α≅2/3 for the pharmaceutical industry. This could provide a simple rationalization for recent mergers or alternatively for portfolio diversification since the same effect could also be achieved in part if each firm held shares in all of its competitors.

Suggested Citation

  • D. Sornette, 2002. "Economies of scale in innovations with block-busters," Quantitative Finance, Taylor & Francis Journals, vol. 2(3), pages 224-227.
    • Handle: RePEc:taf:quantf:v:2:y:2002:i:3:p:224-227
    DOI: 10.1088/1469-7688/2/3/305
    as

    Download full text from publisher

    File URL: http://www.tandfonline.com/doi/abs/10.1088/1469-7688/2/3/305
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1088/1469-7688/2/3/305?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
    2. Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    2. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    3. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    4. Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
    5. Joseph Dimasi & Henry Grabowski & John Vernon, 1995. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 2(2), pages 201-219.
    6. Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
    7. Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
    8. Scherer, F. M. & Harhoff, Dietmar, 2000. "Technology policy for a world of skew-distributed outcomes," Research Policy, Elsevier, vol. 29(4-5), pages 559-566, April.
    9. Hans H. Bauer & Marc Fischer & Volker Pfahlert, 2001. "Lohnt sich für Pharmaunternehmen der Markteintritt als Late Mover? — Ergebnisse einer Rentabilitätsanalyse," Schmalenbach Journal of Business Research, Springer, vol. 53(6), pages 632-648, September.
    10. Lynne G. Zucker & Michael R. Darby, 1995. "Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough," NBER Working Papers 5243, National Bureau of Economic Research, Inc.
    11. Philipp N. Baecker, 2007. "Real Options and Intellectual Property," Lecture Notes in Economics and Mathematical Systems, Springer, number 978-3-540-48264-2, December.
    12. Bauer, Hans H. & Fischer, Marc, 2000. "Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products," International Business Review, Elsevier, vol. 9(6), pages 703-725, December.
    13. Hamdouch, A. & Depret, M.-H., 2000. "Coalitions industrielles, reseaux de firmes et dynamiques de concurrence-cooperation dans les secteurs en cours de globalisation : le cas de l'industrie pharmaceutique," Papiers d'Economie Mathématique et Applications 2000.24, Université Panthéon-Sorbonne (Paris 1).
    14. Didier Sornette, 2007. "Nurturing Breakthroughs: Lessons from Complexity Theory," Papers 0706.1839, arXiv.org.
    15. Yu-Shan Chen & Ke-Chiun Chang, 2009. "Using neural network to analyze the influence of the patent performance upon the market value of the US pharmaceutical companies," Scientometrics, Springer;Akadémiai Kiadó, vol. 80(3), pages 637-655, September.
    16. Thomas Ã…stebro, 1998. "Basic Statistics on the Success Rate and Profits for Independent Inventors," Entrepreneurship Theory and Practice, , vol. 23(2), pages 41-48, December.
    17. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
    18. Yu-Shan Chen & Ke-Chiun Chang, 2010. "The nonlinear nature of the relationships between the patent traits and corporate performance," Scientometrics, Springer;Akadémiai Kiadó, vol. 82(1), pages 201-210, January.
    19. Larkin, Yelena & Lyandres, Evgeny, 2019. "Inefficient mergers," Journal of Banking & Finance, Elsevier, vol. 108(C).
    20. Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:quantf:v:2:y:2002:i:3:p:224-227. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Longhurst (email available below). General contact details of provider: http://www.tandfonline.com/RQUF20 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.